Lilly Adds To Diabetes Pipeline With Protomer Buyout

 
• By Joseph Haas

After investing in the California biotech, Lilly buys the company in search of safer insulin products. The pharma sees these candidates as pairing with tirzepatide to improve diabetes therapy overall.

Insulin ampoule and a syringe isolated against white background
With its buyout of Protomer, Lilly hopes it can develop a safer, more efficacious insulin

More from Deals

More from Business